Press Releases 2017-09-13T20:17:34+00:00

Press Releases

Pfizer’s Xeljanz Barrels into Psoriatic Arthritis, Leaving Lilly’s Recently Launched Taltz in its Wake, According to a Recently Published Study from Spherix Global Insights

Janssen’s Simponi Aria and BMS’ Orencia seem to be settling into their respective niches, but neither brand is anticipated to bring much disruption to the PsA market Download Report Overview EXTON, Pa., April 9, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 101 US rheumatologists reveals uptake of Pfizer’s Xeljanz for the treatment of psoriatic arthritis (PsA) has been much more rapid than that of Eli Lilly’s Taltz. Though launched within weeks of each other, over half of the surveyed rheumatologists have already prescribed Pfizer’s Xeljanz for the treatment of PsA, [...]

April 10, 2018|

Uptake of Merck KGaA’s Mavenclad in the European Multiple Sclerosis Market Currently Stalled Due to Restrictive Guidelines and Pending Additional Country-Level Approvals

Early launch of Roche's Ocrevus has surpassed Mavenclad due to first-in-market primary progressive multiple sclerosis label and broad access through compassionate use programs, although transitioning to country-level health plans may slow future momentum, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., March 27, 2018 /PRNewswire/ -- With an additional six months on the multiple sclerosis (MS) market in the EU, Merck KGaA's Mavenclad trial and uptake has appeared to stall ahead of additional country-level launches. Neurologists surveyed in Q3 2017 anticipated a 45% prescriber base and 2.5% share of disease-modifying therapy (DMT)-treated patients by [...]

March 27, 2018|

Gastroenterologists Are Gearing Up to Incorporate Novel Oral Agents, Such As Pfizer’s Xeljanz, into the Treatment Paradigm for Ulcerative Colitis, According to Latest Data from Spherix Global Insights

Surveyed gastroenterologists (n=101) estimate that 80% of their patients with ulcerative colitis (UC) who were started on a biologic in the past year would have preferred to start with an oral instead, highlighting the massive opportunity not just for Xeljanz, but also for other JAK inhibitors and small molecule agents in the pipeline Download Report Overview EXTON, Pa., March 23, 2018 /PRNewswire/ -- AbbVie's Humira and Janssen's Remicade have been the dominant agents in the moderate-to-severe ulcerative colitis market for years. Recently, Takeda's Entyvio has been gaining momentum, and survey results predict significant gains for Entyvio in UC over the [...]

March 23, 2018|

Genentech’s Ocrevus Begins to Move the Needle on the Treatment Rate for Primary Progressive Multiple Sclerosis but May Not Be the Only Disease-Modifying Therapy in Play

Irrespective of Celgene's recent receipt of a refusal-to-file letter for ozanimod, neurologists are eagerly awaiting a secondary progressive multiple sclerosis indication for Novartis' siponimod, but are more divided on the value EMD Serono's Mavenclad will bring to their practices, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., March 13, 2018 /PRNewswire/ -- The primary progressive multiple sclerosis (PPMS) treatment rate reported by US neurologists (n=101) has increased significantly compared the period prior to Genentech's Ocrevus launch. With almost one-third of Ocrevus-treated PPMS patients on the disease-modifying therapy (DMT) first line, Ocrevus has clearly been [...]

March 13, 2018|

Next Generation Biologics, Janssen’s Tremfya, Eli Lilly’s Taltz, and Novartis’ Cosentyx, Raising the Bar in Psoriasis Management

A recent study published by Spherix Global Insights reveals that the newest psoriasis entrant, Tremfya, has made substantial gains in penetrating first-line biologic therapy for psoriasis. Download Report Overview EXTON, Pa., March 8, 2018 /PRNewswire/ -- The past three years have brought with them a flurry of branded biologic approvals in dermatology, including four biologics for psoriasis alone (Cosentyx in January 2015, Taltz in March 2016, Siliq in February 2017, and Tremfya in July 2017). The new psoriasis options have left many US dermatologists slightly overwhelmed, but also excited that their armamentarium is being regularly refreshed, with each new approval [...]

March 8, 2018|

As Lilly Deals with Yet Another Set-Back in Entering the US Rheumatoid Arthritis Market, Pfizer’s Xeljanz Further Solidifies Its Position as a Go-To Alternate Mechanism of Action Agent, According to a Recently Published Study by Spherix Global Insights

Though baricitinib (Olumiant) has been resubmitted for FDA approval, time lost on the US market has opened up doors for Xeljanz Download Report Overview EXTON, Pa., Feb. 20, 2018 /PRNewswire/ -- Since receiving a Complete Response Letter from the FDA for their Incyte partnered investigational JAK 1/2 inhibitor, baricitinib (Olumiant), Eli Lilly's entrance into the rheumatoid arthritis (RA) market has been met with challenge. Most recently, it has been reported that the company, in partnership with Korea-based Hamni Pharmaceutical, will be ceasing development of its investigational Bruton's TKI inhibitor, LY3337641, due to a lack of efficacy in the RA population. [...]

February 20, 2018|